Cipla EU to form JV in USA

Cell and gene therapy will be top industry trend for pharma in 2024, finds GlobalData

The survey data presented in “The State of the Biopharmaceutical Industry 2024” report reveals that N=21 (18%) of industry professionals were convinced that CGT will dominate as the most important trend in pharma next year

AstraZeneca to acquire China's Gracell Biotechnologies for US $1.2 billion

Furthering cell therapy ambition across oncology and autoimmune diseases

Vertex and CRISPR Therapeutics announce USFDA approval of Casgevy for treatment of sickle cell disease

Approximately 16,000 patients 12 years of age and older with severe sickle cell disease may now be eligible for this one-time treatment

AbelZeta Pharma, AstraZeneca to co-develop a novel GPC3 armored CAR-T therapy in China

C-CAR031 is based on a novel GPC3-targeting CAR-T (AZD5851) designed by AstraZeneca using their transforming growth factor-beta receptor II

Sun Pharma and Pharmazz ink agreement for introducing Tyvalzi in India

Sun Pharma is granted rights for marketing Sovateltide in India under the brand name Tyvalzi (Sovateltide)

USFDA approves BMS’ Reblozyl as first-line treatment of anemia in adults with Myelodysplastic Syndromes

Reblozyl is the first and only therapy to demonstrate superiority compared to an erythropoiesis stimulating agent (ESA) in MDS-related anemia

BlueRock’s Phase I study with bemdaneprocel in patients with Parkinson’s disease meets primary endpoint

Investigational cellular therapy, bemdaneprocel (BRT-DA01), was well tolerated with no major safety issues in all 12 participants in low dose and high dose cohorts through one year / At one-year

Lonza collaborates with Vertex on cell, gene technologies manufacturing

Under the terms of the collaboration, Vertex and Lonza will partner in the process development and scale-up for the manufacturing of the product portfolio and co-invest to build a dedicated new facility in Portsmouth, New Hampshire (US)

Ecolab expands biologics resin manufacturing facility in Pennsylvania

New facility will strengthen the security of supply for global pharmaceutical and biotech customers and will support the continued development and production of lifesaving clinical and commercial-scale therapeutics for patients worldwide.